Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), Boughton Soleil, sold 2,572 shares of Class A Common Stock on July 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $47.82, totaling $122993.
Following the transaction, Boughton Soleil directly owns 158,165 shares of Hims & Hers Health, Inc.
The sale was executed under a Rule 10b5-1 trading plan adopted by Boughton Soleil on August 28, 2024. For deeper insights into insider trading patterns and 15+ additional ProTips about HIMS, consider exploring InvestingPro.
In other recent news, Hims & Hers has been in the spotlight due to several developments. The company faced a significant partnership breakdown with Novo Nordisk (NYSE:NVO), which ended in June 2025. This termination followed disagreements over the sale of compounded semaglutide, leading to Novo Nordisk accusing Hims of illegal sales and deceptive marketing practices. Despite the dispute, Hims & Hers continues to offer Wegovy at retail prices and is considering potential legal action. Meanwhile, the company announced plans to expand its weight loss program into Canada in 2026, aiming to introduce generic semaglutide. This expansion aligns with Hims & Hers’ strategy to leverage generically-available products in new international markets. Morgan Stanley (NYSE:MS) maintained its Equalweight rating on the company, noting the Canadian expansion and ongoing legal concerns. Citi, however, reiterated a Sell rating, expressing skepticism about the pricing opportunities in Canada. Leerink Partners maintained a Market Perform rating, highlighting the potential revenue boost from the Canadian launch while emphasizing the importance of execution and customer uptake.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.